The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

has emerged as a potential indicator of myocardial involvement in cardiac amyloidosis (CA). However, discerning which LGE patterns in amyloidosis distinguish it from other cardiomyopathies remains ...

A cardiac MRI (CMR) then confirmed features of early amyloidosis. Light chains normalized with therapy but repeat bone marrow biopsy showed 5% lambda restricted plasma cells. Given the biopsy results ...

Cardiac amyloidosis is becoming increasingly recognized as an etiology ... (Click here for more results from HELIOS-B presented at ESC Congress 2024.) New therapeutic classes in the pipeline include ...

During ESC Congress 2024, initial results from FINEARTS-HF found ... Do SGLT2 Inhibitors Lower the Risk of Cardiac Dysfunction After Cancer Treatment? In patients with type 2 diabetes (T2D) and cancer ...

The European Society of Cardiology (ESC) Guidelines on cardiomyopathies ... Transthyretin-related cardiac amyloidosis is a progressive disease characterized by the deposition of amyloid protein ...

Endomyocardial biopsy is the only method by which the presence of cardiac amyloidosis can be directly established in cardiac amyloidosis, but this method is invasive, expensive and not always ...

“We believe the addition of the Cortex technology complements our electrophysiology portfolio with a differentiated cardiac mapping offering to assist with complex AF cases,” Nick Spadea ...

The severe cardiac events are often fatal, and while Abrunzo's father survived, it inspired him to take his heart health seriously, since family history is one of the strongest indicators for ...